Colistin: An Update on the Antibiotic of the 21st Century

Silpak Biswas; Jean-Michel Brunel; Jean-Christophe Dubus; Martine Reynaud-Gaubert; Jean-Marc Rolain


Expert Rev Anti Infect Ther. 2012;10(8):917-934. 

In This Article

Five-year View

The usefulness of colistin has been clearly documented along with evidence of less nephrotoxicity than earlier believed. Further studies with colistin should include trials in MDR infections of patients in intensive care unit and reliable susceptibility testing. Further PK and toxicodynamic studies are needed to determine the dosage regimen recommendations of colistin for different patients to maximize the antibacterial activity and minimize the development and prevalence of resistance. Recent approaches to the use of colistin in combination with other antibiotics hold promise for increased antibacterial efficacy. We believe that colistin will be the 'last-line' therapeutic drug against MDR Gram-negative pathogens in the coming years.